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Abstract:  Dietary  proteins  elicit  a  wide  range  of  nutritional  and  biological  functions. 
Beyond their nutritional role as the source of amino acids for protein synthesis, they are 
instrumental in the regulation of food intake, glucose and lipid metabolism, blood pressure, 
bone  metabolism  and  immune  function.  The  interaction  of  dietary  proteins  and  their 
products of digestion with the regulatory functions of the gastrointestinal (GI) tract plays a 
dominant  role  in  determining  the  physiological  properties  of  proteins.  The  site  of 
interaction is widespread, from the oral cavity to the colon. The characteristics of proteins 
that influence their interaction with the GI tract in a source-dependent manner include their 
physico-chemical properties, their amino acid composition and sequence, their bioactive 
peptides, their digestion kinetics and also the non-protein bioactive components conjugated 
with  them.  Within  the  GI  tract,  these  products  affect  several  regulatory  functions  by 
interacting  with  receptors  releasing  hormones,  affecting  stomach  emptying  and  GI 
transport  and  absorption,  transmitting  neural  signals  to  the  brain,  and  modifying  the 
microflora. This review discusses the interaction of dietary proteins during digestion and 
absorption with the physiological and metabolic functions of the GI tract, and illustrates 
the  importance  of  this  interaction  in  the  regulation  of  amino  acid,  glucose,  lipid 
metabolism, and food intake.  
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Ingested proteins have a wide range of nutritional and biological functions. Nutritionally, they are 
essential sources of amino acids and can provide energy. Traditionally, their function and quality have 
been judged primarily on their ability to provide essential amino acids and support protein synthesis. 
However, this focus fails to recognize their influence on many regulatory systems including those 
affecting  amino  acid,  glucose  and  lipid  metabolism,  bone  metabolism,  blood  pressure,  immune 
function,  food  intake  and  body  weight.  Physico-chemical  properties,  amino  acid  composition  and 
bioactive peptides encrypted in amino acid sequences of proteins influence mechanical, hormonal and 
neuroendocrine functions of the gastrointestinal (GI) tract. Therefore, the purpose of this review is to 
discuss  the  qualities  of  dietary  proteins  that  affect  their  actions  during  ingestion,  digestion  and 
absorption on the physiological and metabolic functions of the GI tract. 
In the following, the characteristics of dietary proteins that influence physiology and metabolism 
are reviewed first, followed by an examination of their fate in the GI tract and how they determine the 
role  of  the GI  tract  in  regulating metabolism  and  food  intake.  The final  discussion  proposes  that 
traditional  methods  of  addressing  protein  quality  and  amino  acid  requirements  need  to  take  into 
account the functionality of proteins beyond their role in protein synthesis.  
2. Chemical and Structural Characteristics of Dietary Proteins  
The physiological consequences of ingesting dietary proteins are determined by their food source, 
composition, and matrix and processing. 
2.1. Food Source 
The primary sources of dietary proteins are muscle, milk, egg and plant proteins, and within each 
source is a complex mixture of proteins that affect physiologic regulation in different ways when 
consumed as a mixture or as purified proteins. 
Muscle proteins originate from meat products including red meat, fish and poultry and are divided 
into three groups based on their solubility: sarcoplasmic (e.g., myoglobin), myofibrillar (e.g., myosin 
and actin) and stromal proteins (e.g., collagen and elastin) [1]. Some proteins derived from muscle and 
other animal tissues are used as functional (technological) ingredients in food processing (e.g., collagen 
and  gelatin,  and  beef  plasma  protein).  In  addition  to  traditional  sources  of  meat,  there  are  many 
prepared meat products that include muscle proteins from a variety of sources. The best known product 
of this group is surimi, which is a crude myofibrillar protein concentrate prepared by washing minced, 
mechanically deboned fish muscle from under-utilized marine fish, or mechanically separated chicken 
meat or animal by-products (e.g., beef heart muscle) [1].  
Milk proteins make up 3.5% of cow milk and also comprise a heterogeneous group of proteins, 
which are represented by two major groups: caseins (80%) and whey proteins (20%). Caseins are 
phosphoproteins  and  exist  in  milk  as  large  colloidal  aggregates,  comprised  by  αs1-,  αs2-,  β-  and  
κ-caseins  and  known  as  casein  micelles,  while  whey  proteins,  represented  by  β-lactglobulin,  
α-lactalbumin,  serum  albumin,  immunoglobulins,  lactoferrin  and  proteose-peptone  fractions,  are 
molecularly  dispersed  in  the  solution.  Among  milk  proteins,  only  κ-casein  contains  about  5%  of Nutrients 2011, 3  
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carbohydrates (tri- or tetrasaccharides), consisting of N-acetylneuraminic acid (sialic acid), galactose 
and  N-acetylgalactosamine  [2].  During  cheese-making,  κ-casein  is  hydrolysed  by  chymosin  into  
para-κ-casein  (residues  1–105),  which  remains  with  the  curd,  and  caseinomacropeptide  (residues  
106–169), which becomes a part of sweet whey.  
Milk proteins are ingested not only with dairy products, but also as liquid, concentrated or dried 
food supplements or ingredients widely available on the market [3]. Heterogeneity and complexity of 
milk proteins, determined by their distinct biological and physicochemical properties, provide a wide 
spectrum  in  their  application  as  bioactive  functional  ingredients  to  regulate  food  intake  and  
metabolism [4–6]. 
Egg proteins comprise about 13% of whole egg content, and are morphologically divided into 
proteins of egg white (albumen) and yolk. Ovalbumin, ovotransferrin (conalbumin) and ovomucoid are 
the most abundant proteins of egg white where their content is 54, 12–13 and 11%, respectively, while 
the rest 12–13% are minor proteins (e.g., lysozyme, G2- and G3-globulins, ovoinhibitor, cystatin, 
avidin and others). Egg yolk, when separated by centrifugation, comprises proteins of sedimented 
granules,  and  supernatant  (plasma).  Proteins  of  yolk  granules  include  major  fractions:  α-  and  
β-lipoproteins (70%), phosvitin (16%) and low-density lipoprotein (LDL) (12%), and minor proteins 
such  as  lipovitellin,  phosvitin  and  vitellogenin,  while  yolk  plasma  contains  LDL,  livetins,  yolk 
riboflavin-binding protein and biotin-binding protein [7]. Although egg white is an excellent source of 
high quality protein, it contains ovoinhibitor, the serine proteinase inhibitor that can inhibit digestive 
enzymes  such  as  trypsin  and  chymotrypsin.  This  might  be  an  important  factor  influencing  the 
regulatory functions of the GI tract, especially when raw egg whites are consumed or used for some 
food applications without thermal processing. 
Plant proteins are also complex and cereal, pulse and legume proteins differ in characteristics. 
Cereal proteins from wheat, rye, triticale, barley, maize, sorghum, rice, oat and millet are composed 
of heterogeneous groups of proteins. The amount of protein varies among cereals from as low as 8% in 
rice to 12% in wheat. Cereal proteins, based on their biological functions, are divided into two classes: 
metabolically active (cytoplasmic) proteins and storage proteins. The metabolically active proteins of 
cereals encompass mostly enzymes including protease inhibitors, while storage proteins are divided 
into  albumins  and  the  globulins,  prolamins  and  glutelins.  The  storage  proteins  contain  a  large 
proportion of glutamic acid and proline, and only a small proportion of lysine, arginine and threonine 
and tryptophan. In contrast, the metabolically active proteins contain less glutamic acid and proline, 
and more lysine and arginine. Therefore, they have a higher nutritive value than storage proteins that 
mostly represent endosperm protein, which is the main protein flour [8]. Even though the amino acid 
content varies among species of grains, lysine is the first and tryptophan is the second limiting amino 
acid among all grains. 
Pulse proteins originate from edible seeds of legumes (plants with a pod), which include dry peas, 
beans, lentils and chickpeas. Pulses contain 17–30% of protein, and the major proteins found in pulses 
are globulins (legumin and vicilin) and albumins (enzymatic proteins, protease inhibitors, amylase 
inhibitors  and  lectins).  Unprocessed  pulse  seeds  contain  anti-nutritional  factors  (e.g.,  trypsin  and 
chymotrypsin  inhibitors),  which  decrease  protein  digestibility  if  not  properly  inactivated  during 
processing [9].  Nutrients 2011, 3  
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Soy  proteins  are  derived  from  soy  beans,  which  have  high  protein  content  (35–40%  of  dry  
weight) [10]. Approximately, 90% of the proteins in soybeans exist as storage proteins, primarily  
β-conglycinin, a glycoprotein composed of three sub-units, and glycinin, a hexameric protein, where 
each sub-unit is composed by acidic and basic polypeptides linked together by a disulfide bond [11].  
Proteins from oil-producing plants other than soy: Storage proteins represent the biggest protein 
fraction  in  oilseed  crops,  including  cruciferin  or  12S  protein  in  canola  or  rapeseed,  zein  in  corn,  
11S  protein  in  cottonseed,  12S  protein  in  flax  and  hemp,  arachin in  peanut,  carmin  in  safflower,  
α-globulin in sesame, helianthin in sunflower and others [12]. There are many proteins isolated from  
oil-producing  crops  and  proved  to  be  suitable  for  human  consumption.  All  such  crops  contain  a 
mixture of various proteins (albumins, globulins and glutelins) with different biological functions. 
2.2. Composition 
Many proteins are combined with non-protein components (conjugated proteins), and this affects 
their physiological functions. Casein, as major protein in bovine milk, contains substantial amount of 
phosphorous and calcium in micellar form. Many bioactive components including flavonoids, lectins, 
saponins, phytates, cysteine proteases and trypsin inhibitors contribute to the physiological functions 
of plant proteins. Soy proteins are closely associated with minor components such as isoflavones, 
saponins, trypsin inhibitors, phytic acid, lectin, fibres, and others. Isoflavones (e.g., genistin, daidzin, 
and glycitein) are major soy phytoestrogens present in soy foods [11]. While trypsin inhibitors impact 
pancreatic function and growth in animal models, isoflavones influence the reproductive system [13], 
glucose metabolism [14,15], cancer [16] and cardio-vascular diseases [17].  
2.3. Processing and Matrix Effects 
Due to their polarity, most proteins are soluble in water and alcohol. However processing influences 
the bioavailability and physico-chemical properties of proteins, including solubility, heat lability and 
isoelectric pH, and thereby influences their functional and physiological properties [18,19]. Various 
processing techniques have been applied to facilitate the integration of proteins in food products and  
to  improve  their  nutritional  values.  Texturization,  glycosylation,  chemical  modification  including 
acylation  and  alkylation,  and  enzymatic  modification  including  dephosphorylation  and  plastein 
reactions (e.g., adding or eliminating selected amino acids by formation of peptide bonds) are the most 
common processing techniques [20]. Texturization is a method that confers a fibre-like structure to 
globular proteins and has been applied to many proteins with globular structure (e.g., soy protein, 
wheat  gluten,  and  oilseed  meals)  [21].  Glycosylation  also  constitutes  an  important  processing 
technique  to  improve the functionality of  proteins in food  matrix. Glycosylation of vicilin in  pea 
protein increases its solubility, emulsifying capacity and emulsion stability [22]. Glycosylation may 
also  influence  the  physiological  properties  of  proteins.  For  example,  many  physiological  roles  of 
caseinomacropeptide (CMP), a sub-fragment of κ-casein, are primarily attributed to its glycosylated 
form, glycomacropeptide (GMP) [23]. 
Processing  can  also  be  a  determinant  of  the  amount  and  the  composition  of  the  non-protein 
components:  For  example,  defatted  soy  flour,  which  is  produced  by  grinding  the  defatted  flakes, 
contains 50% protein, while soy protein concentrate, traditionally made by aqueous alcohol extraction Nutrients 2011, 3  
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of defatted soy flakes, contains 70% protein, and soy protein isolate, produced by alkaline extraction of 
the flour followed by precipitation at acid pH, contains more than 90% protein. The concentration of 
isoflavones  in  toasted  soy  flour  is  the  highest  (~3095  μg/g),  followed  by  isolated  soy  protein  
(2161 μg/g) and textured soy protein (~2109 μg/g) [24]. 
Although  various  processing  methods  (e.g.,  thermal  treatment,  high  hydrostatic  pressure  and 
fermentation) elicit favorable effects on dietary proteins by facilitating their integration into various 
food products and by increasing their digestibility and peptide release, negative effects of thermal 
heating  and  dehydration  on  protein  hydrolysates  and  bioactive  peptides  (BAPs)  have  also  been 
reported [25]. 
These chemical and other structural characteristics of proteins as they exist in natural form, in 
processed foods, or in purified forms have many physiological effects beyond the provision of amino 
acids for protein synthesis. The primary impact of these characteristics occurs in the GI tract.  
3. Fate of Dietary Proteins in the Gastrointestinal Tract 
Dietary  proteins  influence  mechanical,  hormonal  and  neuroendocrine  functions  of  the  GI  
tract  throughout  their  digestion,  absorption  and  post-absorption  processes.  The  interaction  of  
protein-digested products with enteric nerves and endocrine systems in the GI tract influences their 
digestion and absorption kinetics and ultimately the metabolic and physiological fate of proteins.  
3.1. Digestion and Absorption of Proteins  
3.1.1. Digestion 
Dietary proteins and peptides are subjected to complex changes during ingestion, digestion and 
absorption. First, hydrolysis of proteins by proteinases (e.g., gastric pepsin and pancreatic trypsin and 
chemotrypsin) results in a pool of peptides, some of which are biologically active. The peptides may 
be further hydrolyzed by peptidases in the pancreatic secretions to small peptides that are digested by 
brush-border peptidases at the surface of the epithelial cells to produce free, di-, tri- and oligo-amino 
acids, or are absorbed. Proteins and peptides present at different stages of digestion may express a 
variety of functions in the GI tract [11,26]. These include the regulation of digestive enzymes, the 
modulation of nutrient absorption in the intestinal tract and other post-absorptive metabolic signals. 
For example, glycomacropeptide (GMP) suppresses protein hydrolysis by inhibiting gastric secretion 
and motility [23]. 
The site of digestion varies depending on the source of proteins. For example, casein, the major 
protein in the bovine milk, precipitates in the stomach where it is hydrolyzed, whilst whey and soy 
protein,  which  are  soluble  proteins,  pass  rapidly  through  the  stomach  and  undergo  digestion  by 
pancreatic enzymes. Because gastric pepsin and pancreatic trypsin have different affinity for bonds 
between amino acids, the site of digestion determines the type of peptides produced by enzymatic 
hydrolysis and consequently their further physiological properties. Pepsin cleaves peptic bonds next to 
aromatic amino acids such as phenylalanine, tryptophan, and tyrosine [27], while trypsin cleaves bonds 
next  to  the  basic  amino  acids  arginine  and  lysine.  Therefore,  unique  physicochemical  properties  Nutrients 2011, 3  
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(e.g., micelles) as well as amino acid sequence of each dietary protein predetermine the course of 
proteolysis and composition of peptides released.  
3.1.2. Absorption 
As with glucose transport, in vitro experiments have shown that active amino acid transport is 
sodium-dependent in a gradient-dependent manner across the brush border membrane of intestinal 
epithelial cells [28]. Variation in the absorption rate of individual amino acids has been shown and this 
rate varies among species [29]. In addition, some amino acids may be transported by more than one 
mechanism (e.g., glycine, proline and hydroxyl proline), making the kinetic absorption of amino acids 
difficult to predict.  
In addition to the rate of digestion and absorption of amino acids, utilization of amino acids by 
splanchnic tissues is a major factor determining the bioavailability of amino acids for other tissues and 
organs. The small intestine, metabolically, is one of the most active tissues in the body [30]. Utilization 
of amino acids by splanchnic tissues is highlighted by the fact that the whole body requirements for 
specific  amino  acids  is  30%  less  with  parenteral  feeding  compared  with  enteral  feeding  in  both  
humans [31] and animals [30]. For example, several non-essential amino acids including glutamine, 
glutamate and aspartate are extensively oxidized in entrocytes, such that almost all in a conventional 
diet do not enter the portal vein [32]. The circulating glutamine is synthesized from branched chain 
amino acids  (BCAA) and  α-ketoglutarate in tissues [33]. In humans, the  splanchnic tissues retain 
between 20–50% of the dietary intake of specific essential amino acids [34,35]. However, BCAA are 
primary exceptions, with approximately 80% of dietary protein content appearing directly in blood 
circulation [36]. In piglets fed milk protein, 40% of leucine and valine and 30% of isoleucine in the 
diet were found to be absorbed by the portal-drained viscera, with less than 20% of the absorbed 
BCAA being utilized for protein synthesis in intestinal mucosa [37].  
3.2. Physiological Significance of Bioactive Peptides in the GI Tract 
Many of the biological and physiological actions of dietary proteins have been attributed to the 
BAPs encrypted in protein molecules [38].  
Digestion and absorption play a key role in the formation and degradation of BAPs [39]. Numerous 
active  peptides  are  produced  during  the  digestion  of  dietary  proteins  in  the  stomach  and  small  
bowel  [40].  Some  BAPs  are  hydrolyzed  during  digestion  to  shorter  active  forms,  such  as  the 
conversion  of  the  peptide  beta-casein  f(133–138)  Leu-His-Leu-Pro-Leu-Pro  (LHLPLP),  a  peptide 
identified in milk fermented with Enterococcus faecalis, to His-Leu-Pro-Leu-Pro (HLPLP) prior its 
transportation across the intestinal epithelium [41]. HLPLP has been detected in human plasma after 
the consumption of a fermented milk enriched with ACE inhibitory peptides [42]. Moreover, the active 
form of milk-derived peptide Lys-Val-Leu-Pro-Val-Pro-Glu (KVLPVPQ) is formed by hydrolysis of 
glutamine during pancreatic digestion [43].  
To be biologically active, it is essential for BAPs to survive proteolysis in the luminal contents of 
the  GI  tract.  The  stability  of  several  BAPs  have  been  reported,  including  casomorphins  [44], 
somatostatin [45], lactoferrin [46] and Epidermal Growth Factor (EGF) [47]. It is still not clear which 
exact characteristics do prevent the breakdown of these BAPs. The stability of BAPs may also vary Nutrients 2011, 3  
 
580 
within a class. The beta-casomorphin-4 (Tyr-Pro-Phe-Pro-NH2) showed no effect on GI transit time, 
while all other types increased GI transit time in a dose-dependent manner [44]. Thus, the authors 
suggested that the latter were more resistant to proteolytic attack and had a higher opioid potency 
than beta-casomorphin-4.  
Dietary  proteins  and  peptides  may  also  influence  the  stability  of  endogenous  peptides  and 
consequently  influence  their  physiological  functions.  For  example,  protein-derived  components  in  
the  digesta  enhance  cholecystokinin  (CCK)  release  by  preventing  the  degradation  of  duodenal  
CCK-releasing factor (CRF), acting as substrates for trypsin. Similarly, trypsin inhibitor compounds, 
which are abundant in soy protein, increase CCK release in both rats [48,49] and humans [50,51] by 
inhibiting the degradation of CRF by trypsin. 
The interaction between protein-digested products and gut peptides, such as CCK, Glucagon-Like 
Peptide 1 (GLP-1), peptide YY (PYY) and ghrelin, also influences GI tract functions and determines 
the metabolic responses to ingested proteins. Hydrolysate forms of casein have a greater effect on food 
intake via CCK-A and opioid receptors than their intact form [52], suggesting a role for casomorphins, 
which have an opioid-like activity, and of GMP, which stimulates the release of CCK [53,54]. The 
progressive and sequential emptying of gastric products also plays an important role in the regulation 
of  gastric  and  pancreatic  secretions  [55].  Yvon  and  colleagues  reported  that  caseinomacropeptide 
(CMP)  is  almost  the  only  peptide  released  from  the  stomach  during  the  first  hour  after  casein  
ingestion [23]. GMP, the glycosylated form of CMP, inhibits gastric secretion and motility [56]. The 
modulating role of CMP on CCK, gastrin and somatostatin release may constitute one of the potential 
mechanisms  through  which  casein  protein  affects  gastric  and  pancreatic  secretions  as  well  as  GI 
motility [57,58]. GMP also suppresses protein hydrolysis and amino acid absorption by inhibiting 
gastric  secretion  and  motility  [23].  Similarly,  β-conglycinin,  a  peptide  derived  from  soy  protein, 
stimulates CCK release [59], and delays gastric emptying and suppresses food intake [59,60].  
Whether the effect of exogenous peptides is limited to their pre-absorptive action in the GI tract or 
remains after they cross the lumen and enter blood circulation is uncertain. Some studies report that the 
mammalian small intestine can absorb gamma-globulins and other milk proteins [61], while some 
others  reported  limited  post-absorptive  bioavailability  of  peptides  [62].  In  humans,  the  peptides 
Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP) were detected undegraded in the 
plasma following the consumption of a lactotripeptide-enriched yogurt beverage [63].  
Several mechanisms for absorption of peptides through epithelial cells have been suggested. Proteins 
and oligopeptides can be transported by transcytosis (vesicle-mediated transcellular transport) [64]. 
However, more than 90% of the proteins and oligopeptides are hydrolyzed intracellularly [65]. Di- and 
tripeptides  are  actively  transported  via  a  specific  transporter  (PepT1)  [66],  but  are  also  further 
hydrolyzed  to  amino  acids  in  the  epithelial  cells.  Proteins  and  peptides  may  also  be  passively 
transported via the paracellular route [67], which is a passive diffusion system that employs a space 
between intestinal epithelial cells [68]. Paracellular transport is regulated by the permeability of tight 
junctions, and some nutrients, including proteins (e.g., β-lactoglobulin), can act as regulators of tight 
junction-mediated  permeability  through  cell  signaling  mechanisms.  Such  mechanisms  involve  the 
recognition  of  nutrients  by  intestinal  epithelial  cell  receptors,  followed  by  signal  transduction  to 
tyrosine kinase, phospholipase C and protein kinase C pathways and resulting in cytosceletal changes 
in tight junctions [69]. This suggests that protein digesta may act synergistically with some proteins Nutrients 2011, 3  
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regulating  the  absorption  rate,  while  other  peptides  have  post-absorptive  effects.  Under  certain 
pathological conditions, paracellular permeability is increased and this, in turn, can increase mucosal 
immune  activity,  enhance  disease  progression  and  severity  and,  possibly,  be  a  risk  factor  for 
development of diseases [70]. This also suggests that the absorption rate of intact proteins and peptides 
may depend on the maturity and health status of the individual. 
Progress in identifying mechanisms of peptide absorption was made by the utilization of Caco-2 
human  intestinal  epithelial  cells,  which  form  a  monolayer  with  tight  junctions  between  cells, 
microvilli,  receptors,  and  expressed  enzymatic  and  transporter  systems  attributable  to  those  cells 
in vivo. Studies with Caco-2 cell lines found that only 2% of the intact tripeptide, VPP, was absorbed 
and detected on the basal side of the monolayer by a paracellular route, while the rest was digested 
either by brush border or intracellular peptidases, including that transported via the peptide transporter, 
PepT1, and hydrolyzed by intracellular peptidases [71]. Supporting evidence for limited transport of 
intact peptides has also been provided by an in vivo study in conscious pigs. The presence of intact 
proline-rich  tripeptides  VPP  and  IPP  in  the  blood  circulation  was  estimated  to  be  approximately  
0.1% of that administered through intragastric infusion via a saline solution. 
Nevertheless,  VPP  and  IPP  are  naturally  present  in  many  fermented  dairy  products  and  their 
consumption  has  been  shown  to  lower  blood  pressure  and  inhibit  angiotensin-converting  enzyme 
(ACE),  the  component  of  rennin-angiotensin  system  (RAS)  [72].  Half-lives  of  absorption  and 
elimination for these peptides were about 5 and 15 min respectively [62]. Absorption of intact proteins 
and peptides was also shown in a study with dogs exposed to intraduodenal infusion of somatostatin. 
Increased concentrations of somatostatin were found in blood [73]. Evidence for absorption has also 
been  shown  by physiological measures. Oral administration  of a daily  dose of  casein hydrolysate 
containing tripeptides VPP and IPP (0.49 g/day) in humans and in hypertensive rats (32 mg/kg BW/day) 
lowered blood pressure [64,74]. Therefore, the physiological effects of BAPs may be due to one of 
efficacy at a very low concentration, an accumulation of an active concentration in certain tissues  
(e.g., aorta) [75–77], an interaction with gut wall or luminal receptors without being absorbed, or a 
combination of these actions. 
4. Protein Sensing in the GI Tract 
The digestion and absorption of proteins in the GI tract affect their physiological and metabolic 
properties and occur through a complex monitoring and control system. The GI tract is the largest 
neuroendocrine  organ  in  the  body,  with  enteric  nervous  and  entero-endocrine  systems  that  are 
integrated within the GI tract and extend to specific areas of the brain [78].  
The GI tract endocrine system produces a large number of peptidergic hormones and regulatory 
factors, localized mainly in the mucosa of the GI tract from the stomach to the rectum and in the 
pancreas. Dozens of hormones and paracrine factors are secreted from the GI tract in response to a 
meal [79], and some of the endocrine cells are directly exposed to ingested bioactive compounds in the 
lumen [80]. Many of the activities of the GI tract, including GI motility, gastric emptying and gastric 
and pancreatic secretions, are under the control of gut peptide hormones that are released in response 
to nutrients in the GI tract [81]. Many gut peptides are also found in the brain and are components  Nutrients 2011, 3  
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of  the  gut-brain  axis  that  regulates  food  intake  and  metabolic  functions  including  blood  glucose  
control [80].  
The enteric nervous system (ENS) of the GI tract communicates with the central nervous system 
(CNS)  through  the  parasympathetic  (e.g.,  via  the  vagus  nerve)  and  sympathetic  (e.g.,  via  the 
prevertebral ganglia) nervous systems [82]. Many of the gut peptides act on GI receptors that relay 
messages to the brain via the afferent vagus nerve [83,84]. Some of the GI hormones, such as CCK, 
PYY, neuropeptide Y (NPY) and somatostatin, originally believed to act on the target digestive organs 
via endocrine pathways, also utilize neural pathways to exert their biological actions [80].  
Signaling  of  protein  ingestion  begins  in  the  oral  cavity  and  finishes  in  the  colon.  Therefore, 
pregastric, gastric, and post-gastric signals are important in determining the physiologic outcomes of 
protein ingestion. 
4.1. Oral and Gastrointestinal Chemosensing 
The chemosensing of the alimentary tract serves to recognize whether the response to stimulus 
(nutrient  or  toxin)  should  be  defensive  (e.g.,  vomiting)  or  nutritional  (digestion,  absorption  and 
storage) [85]. Protein sensing begins with the taste receptors.  
The tongue and the upper GI tract share
 common systems for nutrient sensing that are mediated 
through the vagus nerve, which is extensively distributed throughout the GI tract, from the posterior 
region of the oral cavity and esophagus to the lowest part of the colon. It functions as the primary 
neuroanatomical circuit in the gut-brain axis to transmit meal-related signals from the GI mucosa to 
the central nervous system. Recent findings indicate that taste receptors (T1R and T2R) of taste bulbs 
are  also  expressed  in  the  GI  mucosa.  Conversely,  receptors  for  well-known
  gut  neurotransmitters  
(i.e., serotonin (5-HT)) and hormones (i.e., CCK
 and Vasoactive Intestinal Peptide (VIP)) are also 
expressed in taste buds of the oral cavity. Thus, regulatory processes (e.g., ingestive behavior, nutrient 
absorption, GI secretion, and stomach emptying) as well as conscious sensations (e.g., satiety, nausea, 
and discomfort) begin immediately with food contact [86]. 
Some food proteins and many hydrolysates have a bitter taste due to the presence of peptides whose 
terminal amino acids are hydrophobic, such as isoleucine, tyrosine, phenylalanine, and tryptophan. The 
bitter taste is related to their hydrophobicity, while in intact proteins, hydrophobic amino acid residues 
usually remain inside the molecule and do not interact with taste receptors when ingested with food. 
However, bitterness also decreases at high degrees of conversion, suggesting that bitterness can be 
decreased by cleaving bitter peptides into free amino acids [87]. 
Humans perceive different amino acids in the oral cavity as umami (savory), sweet, bitter, and sour. 
Amino acids infused into different parts of the GI tract, including stomach, duodenum and portal vein, 
may either activate or inhibit vagal afferent activities [85]. For example, intraportal administration of 
Alanine,  Arginine,  Histidine,  Leucine,  Lysine,  Serine,  Tryptophane,  and  Valine,  increased,  while 
Cysteine, Glycine , Phenylalanine, Proline and Threonine decreased vagal afferent discharge rate [88]. 
However,  when  20  different  amino  acids  were  infused  into  the  stomach,  only  glutamate  affected 
gastric vagal afferent activity. The effect of glutamate was suggested to be mediated through serotonin 
receptors (5-HT3) [86]. Similarly, when infused into the duodenum, glutamate was found to increase 
vagal afferent activity [89].  Nutrients 2011, 3  
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Chemical sensing between dietary proteins and enteroendocrine cells is partially mediated by the 
G protein-coupled  family  of  receptors  (T1R  and  T2R).  Such  interactions  between  nutrients  and 
sensitive  cells  trigger  a  complex  response  that  involves  the  release  of  GI  peptides,  with  further 
activation of visceral vagal afferent neurons through the paracrine action. T1Rs receptors mediate 
either sweet taste or sense amino acids or umami, while T2Rs mediate bitter taste [90]. These receptors 
have been found in the taste buds of the lingual epithelium and in different areas of the GI tract 
including gut epithelium and pancreas.  
The T1R system has broad specificity for sweet-sensing and can be activated by natural sugars, 
sweet proteins and artificial sweeteners. In response to glucose, T1Rs stimulate the release of GLP-1 
and Gastric Inhibitory Polypeptide (GIP), and upregulate the sodium-dependent glucose co-transporter 
(SGLT-1)  in  the  intestinal  epithelium  [91,92].  Secreted  GLP-1  interacts  with  GLP-1  receptors 
expressed on vagal afferents and thereby regulates glucose homeostasis [93] and satiety [94].  
The T2R system is believed to have evolved as a protective mechanism against food toxins by 
detecting bitter taste, stimulating food aversion and decreasing gastric emptying [95]. Application of 
ligands for the T2Rs induces rapid Ca
2+ signaling and release of CCK [96]. Intragastric administration 
of either denatonium or phenylthiocarbamide (both bitter compounds) activates neurons in the nucleus 
tractus solitarius (NTS), the region where vagal afferents terminate, and this response is blocked by 
subdiaphragmatic  vagotomy.  Activation  of  the  vagal  pathways  by  denatonium  is  dependent  on 
CCK1Rs and Y2Rs, receptors for CCK and PYY respectively [97,98]. Thus, activation of T2Rs have 
been suggested as a mechanism to decrease gastric emptying and reduce food intake [90]. However, 
the  role  of  individual  food  proteins  and  their  hydrolysates  in  the  physiological  effects  modulated 
through T1R and T2R receptors, localized throughout the GI tract, has not been yet reported. 
4.2. Stomach and Small Intestine 
The stomach determines the rate of appearance and the composition of digesta in the duodenum [55]. 
Gastric  emptying  is  regulated  by  chemical  and  physical  characteristics  of  ingested  meals  [99], 
including osmolality, pH, temperature, viscosity, energy density and volume.  
Ingested proteins and the stomach influence each other in a bi-directional way. Gastric digestion 
and  gastric  emptying  rates  are  major  determinant  of  the  bioavailability  of  amino  acids  and  their 
subsequent utilization [100]. The relatively high importance of ingested protein as a determinant of 
gastric emptying rate is highlighted by the observation that formulas containing the same whey protein 
had similar emptying rates despite having different osmolality and caloric density, which are factors 
known to affect stomach emptying [100]. However, the effects of proteins differ among sources. The 
emptying  rate  of  the  stomach  after  casein  meal  is  slower  as  compared  with  that  following  soy  
meal [101], and it is also longer after the ingestion of casein preload compared with whey preload  
(48  g  protein)  [102].  Gastric  emptying  rate  as  well  as  GI  transit  time  were  also  found  to  be 
significantly longer after casein suspension as compared to whey suspension (0.5 mL), when given to 
rats by gastric tube [44].  
The mechanism by which dietary proteins affect stomach emptying is through their effects on the 
release of gut hormones. CCK, PYY and GLP-1, gut peptides released in response to ingested proteins, 
delay gastric emptying by regulation of pyloric pressure and gastric motility [103–106]. Furthermore, Nutrients 2011, 3  
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GLP-1 causes a moderate and stable flow of gastric emptying via the ―ileal break‖ mechanism [107]. 
In contrast, ghrelin is a gastric peptide stimulating gut motility [108]. Dietary proteins suppress ghrelin 
more than fat and carbohydrate [109]. While most of the described endocrine activities of GI hormones 
are based on the determination of their concentrations in bloodstream, blood concentrations do not 
accurately reflect the whole spectrum of their activities. Exocrine activities of CCK can occur through 
paracrine  mechanisms as a result  of  activation of proximate vagal afferent nerve terminals  [110]. 
Similarly, PYY may function as endocrine, paracrine, and neurocrine transmitters [111]. However, it is 
still not clear whether other GI hormones function through neurocrine mechanisms.  
Proteins or BAPs from them may also stimulate receptors directly. Opioid receptors, which are wide 
spread from stomach to distal colon in rats [112] and from jejunum to distal colon in humans [113], are a 
target for exogenous opioid peptides. Opioid peptides, derived from milk proteins [114], are involved 
in  the  regulation  of  appetite  [52],  plasma  insulin  [115]  and  blood  pressure  [116].  In  addition, 
casomorphins exhibit an antidiarrhoeal effect by prolonging GI transit time and by enhancing net water 
and electrolyte absorption [117]. Furthermore, the intermediary role of peripheral opioid receptors in 
protein-induced satiety has been reported [52,118].  
4.3. Large Intestine 
The large intestine is a primary site of microbial colonization in humans due to its neutral pH, slow 
intestinal motility and very low oxidation/reduction potentials [119]. Ingested proteins and microbiota 
also affect each other in a bi-directional manner. 
Microbiota in the GI tract plays a crucial role in optimum function of the GI tract and prevention of 
infection [120]. In addition, biosynthesis of vitamins (e.g., vitamin B12 and vitamin K) and short-chain 
fatty acids (principally acetate, propionate and butyrate) by microbiota is well-established [121,122]. 
Microbiota can also produce bioactive components from ingested foods [123]. Moreover, microbiota 
may  influence  energy  homeostasis  by  affecting  energy  utilization  from  diet  components  and  by 
altering host genes that regulate energy expenditure and storage [123].  
Protein-derived components, and particularly peptides, have an impact on the composition of the GI 
tract microbiota [124]. Both source and composition of ingested proteins influence the composition 
and metabolic activity of the intestinal microbiota [125]. For example, it has been suggested that whey 
proteins, which leave the stomach quickly, are not hydrolyzed by pancreatic proteinases and could play 
a role in the establishment of the microbiota of the young [126]. Lactoferrin, an iron glycoprotein 
derived  from  whey  protein,  as  well  as  its  sub-fragment  lactoferricin  are  known  to  exert  a  
broad-spectrum primary defence against a wide range of gram negative and positive bacteria, fungi 
(e.g., Candida) and protozoa (e.g., Toxoplasma gondii) both in in vitro and in vivo models [127,128]. 
Anti-viral effects of lactoferricin against several enveloped and naked viruses have also been shown in 
an in vivo model [127]. Similarly, antimicrobial amino acid sequences in casein proteins have been 
identified. Casocidin-I derived from αs2-casein fragment, with a high proportion (10 of 39) of basic 
amino  acid  residues,  have  shown  inhibitory  effects  on  the  growth  of  Escherichia  coli  and 
Staphylococcus carnosus [129]. Similarly, isracidin, derived from αs1-casein, was found protective 
against  Staphylococcus  aureus  and  Candida  albicans  in  mice  [130].  The  mechanisms  by  which 
proteins and their peptides exhibit anti-microbial effects are not clear but three actions have been Nutrients 2011, 3  
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identified.  First,  it  has  been  suggested  that  the  net  positive  charge  of  peptides  released  during  
digestion  plays  a  crucial  role,  destroying  sensitive  microorganisms  by  increasing  cell  membrane  
permeability  [127].  Second,  the  binding  of  enterotoxins  and  the  inhibition  of  viral  and  bacterial 
binding to tissues is another mechanism. For example, GMP has been shown to inhibit the binding of 
cariogenic  bacteria  to  oral  surfaces  [54].  Finally,  nutrient  sequestering  may  be  a  factor.  The 
bacteriostatic effects of lactoferrin are mainly due to its iron sequestering property [127].  
Although excretion of protein in feces has been considered an indicator of low bioavailability of 
dietary proteins, this may underestimate the benefits of protein utilization by microbiota in the large 
intestine [50]. Biosynthesis of indispensible amino acids in the GI tract by microbiota may influence 
total nitrogen balance in humans [131]. Absorption of microbial amino acids has been reported both in 
pigs [132] and humans [131]. Lysine has been utilized as an indicator of absorption of microbial amino 
acids [133]. Between 1–20% of circulating plasma lysine, urinary lysine and body protein lysine of the 
host is derived from intestinal microbial sources [125]. 
The fermentation of proteins by microbiota may produce compounds with adverse metabolic effects 
or reduce their presence. The formation of toxic compounds with metabolic effects includes ammonia, 
dehydrogen  sulphide,  indoles  and  phenols  [134].  However,  luminal  microbes  can  also  deaminate 
amino acids, hydrolyze luminal urea and recycle this ammonia [135]. 
The mechanisms underlying the physiological and metabolic consequences of the interaction of 
ingested proteins and microbiota remain to be described. However, endogenous distal gut peptides 
released from the lower small intestine, such as GLP-1 and PYY, may play a role. In rodents, the 
fermentation of resistant starch by microbiota in the colon has been suggested as a primary mechanism 
for the endogenous production of distal gut peptides GLP-1 and PYY [136–139]. In humans, the 
consumption of prebiotics increases plasma concentrations of GLP-1 and PYY and these responses are 
correlated with increased breath hydrogen excretion, a marker for gut microbiota fermentation [140]. 
Probiotic consumption has also been shown to decrease food intake, body weight gain and fat mass 
development in obese subjects, consistent with the increased PYY and decreased ghrelin postprandial 
responses  in  these  subjects  [141].  Because  GLP-1  and  PYY  are  also  known  as  satiety  signals  in 
response to dietary proteins [104,142], the interaction of protein-digested products with microbiota in 
the GI tract may constitute one of the possible mechanisms underlying the satiating properties of 
dietary proteins. Moreover, an interaction between microbiota and opioid receptors has been reported. 
Lactobacillus acidophilus was found to stimulate opioid and cannabinoid receptors [143].  
5.  Role  of  the  GI  Tract  in  Regulation  of  Metabolism  and  Food  Intake  in  Response  to  
Dietary Proteins  
To  illustrate  the  metabolic  and  physiologic  consequences  of  the  interactions  between  dietary 
proteins and the GI tract, the effects of protein ingestion on the regulation of the metabolism of amino 




5.1.1. Amino Acid Metabolism 
The  source  of  dietary  proteins  affects  amino  acid  kinetics  due  to  several  factors  including  
amino acid composition and their effect on gastric emptying [102,144], the composition of intestinal 
effluents [36], rate of digestion and amino acid absorption, and oxidation [38,61,62].  
Generally, the amount of protein synthesis after protein consumption depends on the match between 
the composition of indispensible amino acids in the dietary protein and the requirement for protein 
synthesis [145], and is offered as an explanation for the lower protein synthesis reported after the 
ingestion  of  soy  protein  compared  with  animal  proteins [145].  In  addition,  the  rate  of  splanchnic 
retention of dietary nitrogen is reported to be directly proportional to protein synthesis, explaining the 
greater protein synthesis observed after ingestion of fast compared with slow proteins [146]. 
Amino acid kinetics, arising from interaction between dietary proteins and the GI tract, has also 
been  proposed  as  a  reason  for  variations  in  their  postprandial  metabolic  effects  [147,148].  For 
example,  caseins  [147]  delay  amino  acid  delivery  to  the  gut  because  their  phosphate-containing 
proteins precipitate under the acidic gastric pH [144]. On the other hand [147], whey remains soluble 
and rapidly passes through the stomach leading to a faster delivery of amino acids to circulation. Thus, 
whey protein ingestion mediates larger increases in post-meal aminoacidemia than casein and leads to 
a higher protein synthesis, whereas casein has a greater effect on reducing protein breakdown [147]. 
Similarly, differences in amino acid kinetics have been reported in studies comparing milk proteins 
(primarily casein) to that of soy protein, a rapidly digested protein [149].  
Although differences in the rate of gastric emptying have been suggested to explain the discrepancy 
in amino acid kinetics observed following the ingestion of casein and whey proteins [144], not all 
studies support this view. Some report a significantly slower rate of gastric emptying after casein 
ingestion  as  compared  to  whey  protein  [102,144],  while  others  described  no  difference  [99].  An 
explanation  for  this  inconsistency  may  reside  in  the  methods  used  to  measuring  gastric emptying  
rate [99,144]. Slower gastric emptying of casein was found when flow rate of the liquid effluents and 
the nitrogen movements after milk protein ingestion was measured by perfusion of saline solution 
containing  phenol  red  [144],  while  no  differences  were  found  in  gastric  emptying  rate  when 
determined by measuring plasma concentrations of paracetamol added to liquid preloads [99]. 
Postprandial amino acid profiles, reflecting the amino acid composition of dietary proteins in addition 
to their rates of digestion, absorption and first pass metabolism in the enterocytes and liver [102], are 
also  influence  the  metabolic and  physiological  consequences  of  ingested  proteins  [99,147,149].  A 
greater increase in blood essential amino acids concentrations following the ingestion of whey protein 
in comparison to either casein or soy protein [150] has been offered as the explanation for the higher 
rate  of  protein  synthesis  reported  in  young  men  after  whey  proteins.  In  addition,  the  higher 
concentrations of indispensable amino acids following the consumption of whey protein as compared 
with casein may lead to higher rates of amino acid deamination and therefore less protection against 
protein breakdown [146,151]. However, individual amino acids have been proposed as factors altering 
protein synthesis. For example, BCAAs and particularly leucine, which represents around 12% of the 
amino  acids  in  whey  protein,  independently  stimulate  muscle  protein  synthesis  [152].  Whey  also Nutrients 2011, 3  
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contains higher concentrations of total sulfur amino acids (methionine and cysteine), lysine, threonine, 
and tryptophan compared to either casein or the complete mix of proteins in milk [146], but their 
individual contribution to the effect of whey protein on protein synthesis has not been explored. 
5.1.2. Glucose Metabolism 
The interactive effect of dietary proteins and glucose metabolism is well established. The effect of 
proteins on glucose metabolism depends on amino acid composition, digestion kinetics of proteins and 
amino acid utilization in the GI tract. When consumed with carbohydrates, dietary proteins reduce 
glycemic responses [153,154]. Amino acids released from proteins have both direct (substrate-mediated) 
and  indirect  (hormone-mediated)  effects  on  glucose  metabolism  [155].  Postprandial  elevation  of 
plasma amino acids increase the secretion of both insulin and glucagon [156,157] and, therefore, alter 
hepatic glucose metabolism by changing the portal insulin/glucagon ratio [158].  
Arginine and the BCAA leucine are known as the most potent amino acids in stimulating pancreatic 
insulin  release  and  therefore  decreasing  plasma  glucose  concentration.  Leucine  also  stimulates 
intracellular insulin signaling in muscles and adipose tissue [159]. Similar effects of ingestion of whey, 
whey hydrolysate or BCAA alone on plasma insulin and glucose concentrations suggest that the effect 
of ingesting whey protein is due to its BCAA content [160]. In addition, the ketogenic and glucogenic 
amino  acid  content  of  proteins  reflect  their  effect  on  gluconeogenesis  and  consequently  glucose 
utilization [145]. 
The rate of protein digestion is also a factor impacting their effect on glucose metabolism. Ingestion 
of  proteinase  inhibitors  delays  gastric  emptying  and  decreases  glucose  and  insulin  plasma 
concentrations  in  type  II  diabetic  patients  [161].  Therefore,  the  rapid  digestion  of  whey  and  the 
resulting increase in insulin release explain in part its greater effect on increasing glucose uptake by 
tissues and reducing plasma glucose concentrations compared with the ingestion of other proteins, 
including casein, that are more slowly digested [99,147]. 
5.1.3. Lipid Metabolism 
Ingestion  of  dietary  proteins  also  contributes  to  the  regulation  of  lipid  metabolism  in  both 
humans [162,163] and animals [164,165], but their effects are source-specific. 
Most  studies  of  dietary  proteins  and  peptides  have  focused  on  plasma  cholesterol  
concentrations [164–168]. Whey protein has a greater hypocholesterolemic effect than either casein or 
soy  protein  in  rats  [168].  Favourable  effects  of  soy  protein  on  plasma  lipid  profile  have  been 
reported [169], but may be in part due to its non-protein bioactive components (e.g., isoflavones) [170]. 
Although egg intake has been reported to increase total serum cholesterol in both animals [171] and 
humans [172], recent studies of egg white proteins [173] and of ovomucin, one of the egg white 
proteins [174], show decreased serum cholesterol concentrations in rats. Beef proteins were found to 
increase plasma cholesterol levels in rabbits [171], have no effect in rats [175] or decrease in rats fed a 
cholesterol-enriched diet [164]. In contrast, fish protein did not show consistent effects on cholesterol 
levels in either rats [164] or rabbits [165]. 
Although the mechanisms by which dietary proteins affect cholesterol metabolism are unclear, their 
effect may be due in part to their BAPs and amino acid composition and to their bile-acid-binding Nutrients 2011, 3  
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capacity  and  hydrophobicity.  The  importance  of  BAPs  is  suggested  by  the  observation  that  a  
high-molecular-weight 11S fraction of soy protein decreased plasma cholesterol and increased fecal 
excretion of steroids to a greater extent than its low-molecular-weight fraction [176]. Similarly, a 
cholesterol-lowering effect of the major fragments of whey protein, α-lactalbumin and β-lactaglobulin 
and their hydrolysates, has been reported [166].  
Protein-digested products, including amino acids, may also play a role in lipid metabolism. Soy 
protein hydrolysates, which were exhaustively hydrolyzed by various methods (microbial or chemical 
hydrolysis), lowered plasma cholesterol more than intact soy protein [176]. High levels of ketogenic 
amino acids in an amino acid mixture were found to influence plasma lipid profile by increasing LDL 
and very low density lipoprotein (VLDL) fragments [177]. Moreover, a significant negative correlation 
between blood cholesterol levels and cysteine content of dietary proteins has been described [178]. 
Bile-acid-binding  capacity  and  hydrophobicity  may  partly  explain  the  hypocholesterolemic 
properties of soy protein [166]. Soy protein inhibits the formation of mixed micelle lipids and bile 
salts, which can subsequently suppress the intestinal absorption of cholesterol and bile acids. On the 
other  hand,  no  relationship  was  observed  between  the  bile-acid-binding  capacity  and  the 
hydrophobicity of whey protein and its hypocholesterolemic action [166]. 
In summary, dietary proteins interact with the physiological functions of the gut to control amino 
acid, glucose and lipid metabolism. In addition, they are significant factors in determining the role of 
the gut in food intake regulation.  
5.2. Food Intake 
The satiety effect of proteins is greater than fat and carbohydrate (cal/cal) [179]. The GI tract plays 
an  important  role  in  the  interplay  between  exogenous  proteins  and  peptides  and  endogenous  
peptide [142]. Protein-induced satiety has been associated with the release of gut peptides such as 
CCK [180], PYY [181], and GLP-1 [182]. Dietary proteins and protein-digested products mediate the 
release of endogenous gut peptides by stimulating chemoreceptors [183] and/or by activating satiety 
hormone  receptors  [52,142,184]  and  others  [59,118].  Again,  protein  source  and  composition  are 
factors for satiety signals. For example, proteins and peptides arising from the digestion of casein and 
soy protein suppress food intake through opioid and CCK-1 receptors [52], whereas those from whey 
and casein interact with exendin-4, a GLP-1 receptor agonist, to suppress food intake in rats [142]. 
In humans, whey protein suppresses short-term food intake to a greater extent than egg albumen and 
soy protein isolate in young men [185].  
The  variable  effects  of  dietary  proteins  on  food  intake  may  be  due  to  the  differences  in  their 
structure,  their  amino  acid  composition  and  the  bioactive  peptides  encrypted  in  their  amino  acid 
sequences. Protein source influences digestion, gastric emptying [186,187], and the composition of 
intestinal effluents [188]; the rate of amino acid absorption and oxidation [147,189,190]; plasma and 
brain amino acid concentrations and patterns [191,192]; and insulin and glucagon release [193,194]. 
All have been associated with decreased food intake.  
The effect of individual amino acids and BAPs as protein-digested products on food intake has been 
reported. Hydrolysates of proteins suppress food intake more than intact protein [52], suggesting a role 
for both free amino acids and BAPs. Elevated plasma concentrations of individual amino acids can Nutrients 2011, 3  
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directly influence certain areas of the hypothalamus involved in food intake regulation. The precursor 
roles  in  the  brain  of  increased  tryptophan  and  histidine  on  the  synthesis  of  the  neurotransmitters 
serotonine and histamine, and of tyrosine on the neurotransmitters dopamine and norepinephrine, have 
been shown [195–197]. The intracerebroventricular administration of leucine decreases food intake 
and body weight in rodents although the mechanism is unclear [198,199].  
Evidence supporting activity of dietary protein derived BAPs on satiety and food intake has been 
reported. For example, casein-derived GMP suppressed food intake through the first half an hour of 
food intake more than whey, casein and complete milk protein in rats [200]. In humans, whey protein 
containing  GMP  decreased  energy  intake  to  a  greater  extent  at  three  hours  following  breakfast 
consumption than whey protein alone [201]. The satiety effect of β-conglycinin, a peptide originated 
from soy protein, has been also shown in rats [60,202]. 
It is clear that the interaction of dietary proteins with regulatory functions of the GI tract have 
profound effects on physiologic and metabolic responses. However, at the present time, there is no 
standard method for describing physiologic properties of dietary proteins, analogous to the glycemic 
index used to describe the metabolic characteristics of carbohydrates. 
6. Assessment of Protein Quality 
Historically, many methods have been used to rank protein quality based on their digestibility, 
absorption of amino acids and capacity to provide metabolically active nitrogen and amino acids to 
tissues  and  organs.  Such  methods  integrate  the  estimates  of  experimentally-derived  amino  acid 
requirement with the knowledge of the capacity of food proteins to efficiently meet these amino acid 
requirements.  Amino  acid  requirement  studies  have  traditionally  used  plasma  amino  acid 
concentrations,  amino  acid  oxidation  and  amino  acid  balance  methodologies  [203].  Recently,  the 
indicator  amino  acid  oxidation  (IAAO)  method,  using  14C-  or  13C-carbon  labelled  amino  acid 
oxidation, has been applied to determine almost all indispensable amino acid requirements in adult 
humans [204]. It is based on the concept that excess amino acids cannot be stored and therefore must 
be partitioned between incorporation into proteins or oxidation. When one of the indispensable amino 
acids is deficient for protein synthesis, all other amino acids, including the indicator labelled amino 
acid, are available in excess and are consequently oxidized. Thus, with increasing intake of the limiting 
amino acid, oxidation of the indicator amino acid will decrease, reflecting an increased incorporation 
into protein synthesis. The requirement for the amino acid under test is determined by the amount after 
which no further increases bring about a reduction in the oxidation of the indicator amino acid. 
Protein  quality  assessment  methods  measure  the  effects  of  protein  ingestion  under  controlled 
conditions  on  nitrogen  excretion,  growth,  and  protein  synthesis  or  calculate  protein  quality  based  
on  amino  acid  composition  of  the  test  protein  compared  to  a  reference  standard.  The  Protein  
Digestibility-Corrected Amino Acid Score (PDCAAS) is the currently recommended method of choice 
for routine assessment of protein quality of foods to meet human requirements [205]. It is based on the 
combination of an age-related amino acid reference pattern, which is reflective of estimates of human 
requirements, and of protein digestibility. It has been noted previously that the estimates of protein 
quality fail to consider the physiological activities of protein-derived components as determinants of 
amino acid utilization for protein synthesis [206].  Nutrients 2011, 3  
 
590 
Perhaps, equally worth noting is that the accuracy of amino acid requirements based on the IAAO 
method may be questioned for this reason. It also fails in its methodology to mimic the multitude of 
effects of protein ingestion on protein synthesis through physiologic effects independent of their role 
of providing amino acids for protein synthesis. Determination of amino acid requirements through the 
IAAO method is based on feeding defined amino acid mixtures to test subjects over eight hours [204]. 
Thus,  estimates  of  amino  acid  requirements  may  not  reflect  the  true  amino  acid  requirement  as 
influenced by physiological and metabolic effects of protein ingestion before amino acid absorption 
occurs. To our knowledge, there are no reports comparing the effects of acute or chronic consumption 
of an intact protein with an amino acid mixture of the same amino acid composition on gut hormone 
and metabolic responses and protein synthesis and degradation. 
7. Summary and Conclusion 
The importance of the interaction of the chemical and physical structure of food proteins with the 
regulation of metabolism and food intake has received considerable attention in the past fifteen years. 
This review has illustrated the importance of the interaction of dietary proteins during digestion and 
absorption with the physiological and metabolic functions of the GI tract, in the regulation of amino 
acid, glucose, lipid metabolism, and food intake. Dietary proteins and their digested products interact 
with the regulatory functions of the gastrointestinal (GI) tract in a source dependent manner. Within 
the GI tract, dietary proteins and their products of digestion affect several regulatory functions by 
interacting  with  receptors  releasing  hormones,  affecting  stomach  emptying  and  GI  transport  and 
absorption, transmitting neural signals to the brain, and modifying the microflora. The characteristics 
of  proteins  including  their  physico-chemical  properties,  amino  acid  composition  and  sequence, 
bioactive peptides, digestion kinetics and also non-protein bioactive components conjugated with them 
influence their interaction with the GI tract. Yet, there are currently no assessment methods designed 
to  evaluate  the  physiological  quality  of  proteins  beyond  providing  indispensable  amino  acids  and 
contributing to protein synthesis. Clearly, the role of dietary proteins as determinants of health has to 
be understood beyond that provided by the traditional methods of assessment of protein quality. 
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